Biogen (BIIB) Cash from Operations Growth (1y) (2010 - 2026)
Biogen (BIIB) Cash from Operations Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (1y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
11.07% |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
220.11% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
-39.77% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
134.19% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
56.72% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
57.37% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
44.79% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
11.99% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
-43.50% |
| 10 |
Biogen |
28.75 Bn |
24.47 Bn |
1.82 Bn |
148.94% |
| Date | Value |
|---|
| Mar 31, 2026 |
148.94% |
| Dec 31, 2025 |
-32.72% |
| Sep 30, 2025 |
36.01% |
| Jun 30, 2025 |
-74.29% |
| Mar 31, 2025 |
-53.13% |
| Dec 31, 2024 |
5,987.20% |
| Sep 30, 2024 |
57.93% |
| Jun 30, 2024 |
28.50% |
| Mar 31, 2024 |
21.50% |
| Dec 31, 2023 |
107.14% |
| Sep 30, 2023 |
-10.38% |
| Jun 30, 2023 |
-33.88% |
| Mar 31, 2023 |
181.40% |
| Dec 31, 2022 |
-120.88% |
| Sep 30, 2022 |
-17.92% |
| Jun 30, 2022 |
-39.99% |
| Mar 31, 2022 |
-78.96% |
| Dec 31, 2021 |
328.36% |
| Sep 30, 2021 |
-31.82% |
| Jun 30, 2021 |
-37.01% |
